Weekly injections of semaglutide, the active ingredient in Ozempic and Wegovy, led to significant reductions in body weight and knee osteoarthritis-related pain, according to a phase 3 study by Novo Nordisk.
Paige Twenter is a reporter for Becker's Healthcare, focusing on national healthcare news in the United States. With a keen interest in supply chain management, hospital operations, and healthcare policy, Paige covers a range of topics including supplier diversity, medical shortages, sepsis prevention, and the impact of technology on healthcare delivery.